A study was conducted to evaluate the early results of high-dose-rate superficial brachytherapy (HDR-SB) after keloidectomy. Between April 2008 and April 2009, 21 patients with 36 histologically confirmed keloids were treated with postoperative HDR-SB. The tube applicator was placed on the skin to match the area of the surgical wound, and a spacer 5 mm thick was placed between the skin and the applicator. A dose evaluation point was established below 2 mm from skin surface, and 20 Gy was delivered in 4 daily fractions to keloidectomy scars on the anterior chest wall, scapular region, lower jaw and suprapubic region. A dose of 15 Gy was delivered in 3 daily fractions to lesions in other areas. The median follow-up period was 18 months (range, 9 to 29 months). Therapeutic outcome was judged in terms of recurrence, control, or acute side effects. Three keloids (9.7%) in two patients showed local recurrence, with a median time to failure after HDR-SB of 12 months. All recurrences affected the anterior chest wall. Dysraphia occurred in only one patient with an anterior chest wall lesion. Excluding the cases of recurrence, acceptable cosmetic results were achieved. Our results indicate that HDR-SB is effective and safe for preventing recurrence of keloids.
Traditionally, cervical brachytherapy has been prescribed to point A. However, since the Groupe Européen de Curiethérapie and European Society for Radiotherapy Oncology guidelines were published, image-guided brachytherapy has become an emerging technique. The purpose of this study was to evaluate the highrisk clinical target volume HR-CTV coverage and analyze dose-volume histograms for organs at risk in point A prescription of high-dose-rate brachytherapy. A total of 68 patients with locally advanced cervical cancer were treated with three-dimensional conformal external beam radiation therapy and brachytherapy from December 2012 to March 2017. Fractions of 6 Gy for a total of 12-24 Gy were delivered at point A by brachytherapy to all patients. Following each brachytherapy application, a pelvic computed tomography scan was performed and imported into a threedimensional brachytherapy treatment planning system. In this study, the HR-CTV, bladder, and rectum were re-delineated according to Report 89 of the International Commission on Radiation Units and Measurements using the magnetic resonance images at the time of diagnosis, and the dose-volume histogram of each structure was analyzed. The median age of patients at diagnosis was 67 years range, 31-91 years. Mean HR-CTV D 90 for all patients was 558.3 cGy range, 228.7-1005.1 cGy and the mean HR-CTV D 90 within each clinical T stage was : Ib, 646.4 cGy ; 2a, 579.3 cGy ; 2b, 545.2 cGy ; 3a, 556.6 cGy ; 3b, 451.3 cGy ; and 4, 497.9 cGy. HR-CTVD 90 was correlated with HR-CTV. The mean D2 cm 3 was 678.1 cGy for the bladder and 511.9 cGy for the rectum. Using point A-based dose prescription, HR-CTV coverage was insufficient, especially in cases with a large tumor volume or a high T stage. Image-guided brachytherapy is expected to improve HR-CTV coverage while keeping rectal and bladder doses within acceptable levels.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.
hi@scite.ai
10624 S. Eastern Ave., Ste. A-614
Henderson, NV 89052, USA
Copyright © 2024 scite LLC. All rights reserved.
Made with 💙 for researchers
Part of the Research Solutions Family.